EnGen Bio
Redwood City
About EnGen Bio
EnGen Bio is a development-stage biotechnology company that pioneers a new approach to preventing and treating influenza. It believes that it has identified a candidate Universal Type A Influenza vaccine. Influenza drugs and vaccines are unique because there is sufficient government funding available to develop these assets well into human clinical trials, and possibly to market. EnGen Bio is aggressively pursuing this and similar opportunities. It is founded in 2017 and is headquartered in Redwood City, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $812.0K
- Funding stage: Seed
- Last round: Seed (Jan 2020)
- Website: engenbio.com
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science
Canonical: https://fsome.com/organization/engen-bio-197008 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.